Health Catalyst, Inc. (NASDAQ:HCAT) Insider Linda Llewelyn Sells 6,441 Shares

Health Catalyst, Inc. (NASDAQ:HCAT) insider Linda Llewelyn sold 6,441 shares of the firm’s stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $5.43, for a total transaction of $34,974.63. Following the completion of the sale, the insider now directly owns 85,819 shares in the company, valued at $465,997.17. This represents a 6.98 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Linda Llewelyn also recently made the following trade(s):

• On Wednesday, January 15th, Linda Llewelyn sold 6,442 shares of Health Catalyst stock. The stock was sold at an average price of $5.80, for a total transaction of $37,363.60.
• On Monday, December 16th, Linda Llewelyn sold 6,442 shares of Health Catalyst stock. The stock was sold at an average price of $7.88, for a total transaction of $50,762.96.

Health Catalyst Stock Down 2.9 %

Shares of HCAT traded down $0.16 during mid-day trading on Thursday, reaching $5.39. 456,933 shares of the stock traded hands, compared to its average volume of 774,837. The firm has a market cap of $327.97 million, a price-to-earnings ratio of -3.99 and a beta of 1.34. The stock has a fifty day simple moving average of $6.35 and a 200 day simple moving average of $7.31. Health Catalyst, Inc. has a 12-month low of $5.25 and a 12-month high of $9.72. The company has a quick ratio of 1.41, a current ratio of 1.41 and a debt-to-equity ratio of 0.32.

Institutional Trading of Health Catalyst

A number of hedge funds have recently made changes to their positions in HCAT. First Light Asset Management LLC raised its stake in shares of Health Catalyst by 22.0% during the fourth quarter. First Light Asset Management LLC now owns 5,241,121 shares of the company’s stock valued at $37,055,000 after purchasing an additional 944,631 shares during the period. Alyeska Investment Group L.P. raised its stake in shares of Health Catalyst by 74.4% during the fourth quarter. Alyeska Investment Group L.P. now owns 2,019,380 shares of the company’s stock valued at $14,277,000 after purchasing an additional 861,150 shares during the period. Fred Alger Management LLC purchased a new stake in shares of Health Catalyst during the third quarter valued at approximately $6,858,000. Portolan Capital Management LLC purchased a new stake in shares of Health Catalyst during the third quarter valued at approximately $5,402,000. Finally, Kennedy Capital Management LLC grew its position in shares of Health Catalyst by 42.7% during the fourth quarter. Kennedy Capital Management LLC now owns 1,891,000 shares of the company’s stock worth $13,369,000 after buying an additional 565,445 shares in the last quarter. Hedge funds and other institutional investors own 85.00% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently issued reports on the stock. Royal Bank of Canada decreased their target price on shares of Health Catalyst from $9.00 to $7.00 and set a “sector perform” rating on the stock in a research report on Wednesday, January 15th. Stephens raised their price target on shares of Health Catalyst from $7.00 to $9.00 and gave the company an “equal weight” rating in a report on Thursday, November 14th. Piper Sandler cut their price target on shares of Health Catalyst from $12.00 to $8.00 and set an “overweight” rating on the stock in a report on Tuesday, February 11th. Wells Fargo & Company cut their price target on shares of Health Catalyst from $13.00 to $10.00 and set an “overweight” rating on the stock in a report on Tuesday, January 21st. Finally, Canaccord Genuity Group cut their price target on shares of Health Catalyst from $11.00 to $10.00 and set a “buy” rating on the stock in a report on Tuesday, January 21st. Two analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to MarketBeat, Health Catalyst presently has a consensus rating of “Moderate Buy” and a consensus target price of $10.20.

About Health Catalyst

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.